» Articles » PMID: 32869850

Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years

Abstract

Context: Patients with craniopharyngioma suffer from obesity and impaired bone health. Little is known about longitudinal changes in body composition and bone mineral density (BMD).

Objective: To describe body composition and BMD (change).

Design: Retrospective longitudinal study.

Setting: Two Dutch/Swedish referral centers.

Patients: Patients with craniopharyngioma (n = 112) with a dual X-ray absorptiometry (DXA) scan available (2 DXA scans, n = 86; median Δtime 10.0 years; range 0.4-23.3) at age ≥ 18 years (58 [52%] male, 50 [45%] childhood onset).

Main Outcome Measures: Longitudinal changes of body composition and BMD, and associated factors of ΔZ-score (sex and age standardized).

Results: BMI (from 28.8 ± 4.9 to 31.2 ± 5.1 kg/m2, P < .001), fat mass index (FMI) (from 10.5 ± 3.6 to 11.9 ± 3.8 kg/m2, P = .001), and fat free mass index (FFMI) (from 18.3 ± 3.2 to 19.1 ± 3.2 kg/m2, P < .001) were high at baseline and increased. Fat percentage and Z-scores of body composition did not increase, except for FFMI Z-scores (from 0.26 ± 1.62 to 1.06 ± 2.22, P < .001). Z-scores of total body, L2-L4, femur neck increased (mean difference 0.61 ± 1.12, P < .001; 0.74 ± 1.73, P < .001; 0.51 ± 1.85, P = .02). Linear regression models for ΔZ-score were positively associated with growth hormone replacement therapy (GHRT) (femur neck: beta 1.45 [95% CI 0.51-2.39]); and negatively with radiotherapy (femur neck: beta -0.79 [-1.49 to -0.09]), glucocorticoid dose (total body: beta -0.06 [-0.09 to -0.02]), and medication to improve BMD (L2-L4: beta -1.06 [-1.84 to -0.28]).

Conclusions: Z-scores of BMI, fat percentage, and FMI remained stable in patients with craniopharyngioma over time, while Z-scores of FFMI and BMD increased. Higher glucocorticoid dose and radiotherapy were associated with BMD loss and GHRT with increase.

Citing Articles

Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy.

Chiloiro S, Vicari A, Mongelli G, Costanza F, Giampietro A, Mattogno P Rev Endocr Metab Disord. 2024; 25(5):855-873.

PMID: 39168952 PMC: 11470908. DOI: 10.1007/s11154-024-09898-6.


Hypogonadism as a consequence of craniopharyngioma in female patients: comparison of childhood and adult onset and effects of estrogen replacement therapy.

Ilovayskaya I, Zektser V Endocrine. 2024; 85(3):1425-1434.

PMID: 38761348 DOI: 10.1007/s12020-024-03872-7.


Comprehensive Insights Into Pediatric Craniopharyngioma: Endocrine and Metabolic Profiles, Treatment Challenges, and Long-term Outcomes from a Multicenter Study.

Siklar Z, Ozsu E, Kizilcan Cetin S, Ozen S, Cizmecioglu-Jones F, Balki H J Clin Res Pediatr Endocrinol. 2024; 16(3):288-296.

PMID: 38664994 PMC: 11590763. DOI: 10.4274/jcrpe.galenos.2024.2024-1-3.


Commentary: Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.

Andereggen L, Christ E Front Endocrinol (Lausanne). 2024; 15:1371424.

PMID: 38476669 PMC: 10928441. DOI: 10.3389/fendo.2024.1371424.